Kremers Urban: Mastering the Complexities of the Market

Getting pharmaceutical products to market is hard enough. Challenges such as active pharmaceutical ingredients (API), formulation, drug delivery technology, and manufacturing difficulties can make the task seem even more insurmountable. KREMERS URBAN, LLC is a pharmaceutical company that delivers the product solutions and dedicated customer service needed to get specialty generic products to market without all the perplexity.

Providing Leadership Through the Drug Development Maze

Many promising drugs are abandoned early because of difficult-to-synthesize ingredients, complicated formulations, manufacturing issues, or legal challenges. KREMERS URBAN, LLC, a subsidiary of Belgium-based UCB, strives to deliver the tough solutions and reliable service that get products to market. The Company’s focus is providing a wide array of generic pharmaceuticals—particularly those products with difficult-to-produce or limited-supply API or finished goods formulations, dedicated containment facilities, or Paragraph IV challenges–and biosimilar products. It is a strategy that is achieved through a combination of internal development and strategic partnerships.

The vision of KREMERS URBAN, LLC is to be a premier, specialty generic pharmaceutical company with a portfolio of high-barrier-to-entry products and limited competition. Leveraging the vast resources of its parent company, KREMERS URBAN, LLC is moving to the forefront of delivering the tough solutions necessary to get complex products into the market. Its professionals are experts at increasing efficiencies and reducing the cost of getting generic products to the appropriate market segments. The newest product in the portfolio is generic Oxybutynin Chloride Extended-Release Tablets USP, an extended-release drug that requires a complex drug development technology and manufacturing process. KREMERS URBAN, LLC also manufactures and distributes Omeprazole Delayed-Release Capsules, Nifedipine Extended-Release Tablets USP, Verapamil Hydrochloride Extended-Release Capsules, and several other extended-release and transdermal generic products. The Company stands behind each of its products, ensuring the highest standards available.

In addition to aggressively pursuing in-licensing generic drug products and internal research and development, KREMERS URBAN, LLC looks to expand its generic product portfolio by leveraging the biopharmaceutical capabilities being developed by UCB. The Company seeks strategic alliances in the development of products and drug delivery technologies that would further enhance its capabilities or offerings.

A History of Solving Our Customers’ Toughest Problems

The history of KREMERS URBAN, LLC dates back more than a century. The Company was acquired by SCHWARZ PHARMA Manufacturing, Inc. in the mid-90s before SCHWARZ PHARMA Manufacturing, Inc. was acquired by UCB in 2006. KREMERS URBAN, LLC has made impressive strides since it embarked on its own. The business continues to excel in its service and capabilities. Fill rates, lead times, and service levels consistently attain 100%, meeting or exceeding all of its customers’ expectations. All this has recently translated to major corporate growth and more extensive capabilities. Along with commercial offices in Princeton, New Jersey, it has recently relocated its customer service headquarters to Seymour, Indiana, where it has also invested in an impressive 400,000-square-foot pharmaceutical manufacturing plant. With its dedicated facilities, comprehensive infrastructure, technical expertise, and UCB corporate support, the Company is uniquely structured and positioned to manage high barriers to entry.

Whether it is complex API, drug delivery systems, or challenging product formulations, you can trust its professionals to complete the complicated puzzle of market entry, and KREMERS URBAN, LLC to master the complexities of the marketplace.

For more information, visit www.kremersurbanllc.com.

Rubik’s Cube® used by permission of Seven Towns Ltd. www.rubiks.com